相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Pathological activation of KIT in metastatic tumors of acral and mucosal melanomas
Atsuko Ashida et al.
INTERNATIONAL JOURNAL OF CANCER (2009)
Phase II trial of imatinib mesylate in patients with metastatic melanoma
K. B. Kim et al.
BRITISH JOURNAL OF CANCER (2008)
KIT Gene Mutations and Copy Number in Melanoma Subtypes
Carol Beadling et al.
CLINICAL CANCER RESEARCH (2008)
Imatinib Targeting of KIT-Mutant Oncoprotein in Melanoma
Xiaofeng Jiang et al.
CLINICAL CANCER RESEARCH (2008)
Major response to imatinib mesylate in KIT-mutated melanoma
F. Stephen Hodi et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Dose-dependent, complete response to imatinib of a metastatic mucosal melanoma with a K642E KIT mutation
Jose Lutzky et al.
PIGMENT CELL & MELANOMA RESEARCH (2008)
Sorafenib inhibits the imatinib-resistant KITT6701 gatekeeper mutation in gastrointestinal stromal tumor
Tianhua Guo et al.
CLINICAL CANCER RESEARCH (2007)
Solar elastosis in cutaneous melanoma
Robin T. Vollmer
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2007)
L576P KIT mutation in anal melanomas correlates with KIT protein expression and is sensitive to specific kinase inhibition
Cristina R. Antonescu et al.
INTERNATIONAL JOURNAL OF CANCER (2007)
Distinct clinical and pathological features are associated with the BRAF T1799A(V600E) mutation in primary melanoma
Wendy Liu et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2007)
Somatic activation of KIT in distinct subtypes of melanoma
John A. Curtin et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
MC1R germline variants confer risk for BRAF-mutant melanoma
Maria Teresa Landi et al.
SCIENCE (2006)
Multicenter phase II trial of high-dose imatinib mesylate in metastatic melanoma - Significant toxicity with no clinical efficacy
K Wyman et al.
CANCER (2006)
BRAF somatic mutations in malignant melanoma and melanocytic naevi
NE Thomas
MELANOMA RESEARCH (2006)
Distinct sets of genetic alterations in melanoma
JA Curtin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
An immunohistochemical evaluation of c-kit (CD-117) expression in malignant melanoma, and results of imatinib mesylate (Gleevec) therapy in three patients
JB Alexis et al.
MELANOMA RESEARCH (2005)
Lack of clinical efficacy of imatinib in metastatic melanoma
S Ugurel et al.
BRITISH JOURNAL OF CANCER (2005)
Biology of gastrointestinal stromal tumors
CL Corless et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Determinants of BRAF mutations in primary melanomas
JL Maldonado et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2003)
Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor
MC Heinrich et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations
YS Ma et al.
BLOOD (2002)
Kit signal transduction
ML Taylor et al.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2000)
分享论文
